Taiko Pharmaceutical Co.,Ltd. (4574.T)
JPY 273.0
(-1.44%)
JPY 273.0
(-1.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -3.07 Billion JPY | 37.77% |
| 2021 | -4.94 Billion JPY | -187.56% |
| 2020 | 5.65 Billion JPY | 47.75% |
| 2019 | 3.82 Billion JPY | 88.41% |
| 2018 | 2.02 Billion JPY | 9.31% |
| 2017 | 1.85 Billion JPY | 20.17% |
| 2016 | 1.54 Billion JPY | 14.67% |
| 2015 | 1.34 Billion JPY | -47.34% |
| 2014 | 2.55 Billion JPY | -1.22% |
| 2013 | 2.59 Billion JPY | 131.11% |
| 2012 | 1.12 Billion JPY | 117.67% |
| 2011 | 515 Million JPY | 141.45% |
| 2010 | -1.24 Billion JPY | -149.92% |
| 2009 | 2.48 Billion JPY | 178.32% |
| 2008 | 894.37 Million JPY | 33.06% |
| 2007 | 672.14 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q3 | -48 Million JPY | 80.08% |
| 2023 Q2 | -241 Million JPY | -55.48% |
| 2023 Q1 | -155 Million JPY | 52.89% |
| 2022 Q3 | -333 Million JPY | 55.3% |
| 2022 FY | -3.07 Billion JPY | 37.77% |
| 2022 Q4 | -329 Million JPY | 1.2% |
| 2022 Q1 | -1.67 Billion JPY | 50.37% |
| 2022 Q2 | -745 Million JPY | 55.44% |
| 2021 Q1 | -190 Million JPY | 0.0% |
| 2021 Q2 | -2.09 Billion JPY | -1000.0% |
| 2021 FY | -4.94 Billion JPY | -187.56% |
| 2021 Q4 | -3.36 Billion JPY | -579.91% |
| 2021 Q3 | 702 Million JPY | 133.59% |
| 2020 FY | 5.65 Billion JPY | 47.75% |
| 2020 Q1 | 621.17 Million JPY | -72.05% |
| 2020 Q3 | 1.48 Billion JPY | -46.3% |
| 2020 Q2 | 2.75 Billion JPY | 343.92% |
| 2019 Q2 | 180.85 Million JPY | 36.56% |
| 2019 FY | 3.82 Billion JPY | 88.41% |
| 2019 Q1 | 132.43 Million JPY | -89.43% |
| 2019 Q3 | 799.97 Million JPY | 342.34% |
| 2019 Q4 | 2.22 Billion JPY | 177.83% |
| 2018 Q4 | 1.25 Billion JPY | 115.17% |
| 2018 Q3 | 582.46 Million JPY | 843.5% |
| 2018 Q1 | -25.81 Million JPY | -101.87% |
| 2018 Q2 | 61.73 Million JPY | 339.17% |
| 2018 FY | 2.02 Billion JPY | 9.31% |
| 2017 Q3 | 321.29 Million JPY | 77.0% |
| 2017 Q2 | 181.52 Million JPY | 184.71% |
| 2017 Q1 | -214.29 Million JPY | -116.67% |
| 2017 FY | 1.85 Billion JPY | 20.17% |
| 2017 Q4 | 1.38 Billion JPY | 329.52% |
| 2016 Q4 | 1.28 Billion JPY | 173.08% |
| 2016 FY | 1.54 Billion JPY | 14.67% |
| 2016 Q3 | 470.65 Million JPY | 12374.29% |
| 2016 Q2 | 3.77 Million JPY | -94.16% |
| 2016 Q1 | 64.61 Million JPY | -92.7% |
| 2015 Q2 | 150.32 Million JPY | 394.9% |
| 2015 Q1 | 30.37 Million JPY | -98.05% |
| 2015 Q4 | 885.19 Million JPY | 257.56% |
| 2015 FY | 1.34 Billion JPY | -47.34% |
| 2015 Q3 | 247.56 Million JPY | 64.69% |
| 2014 Q4 | 1.55 Billion JPY | 180.87% |
| 2014 Q3 | 555.19 Million JPY | 34.01% |
| 2014 Q1 | -28.28 Million JPY | -102.4% |
| 2014 Q2 | 414.29 Million JPY | 1564.85% |
| 2014 FY | 2.55 Billion JPY | -1.22% |
| 2013 Q1 | -173.31 Million JPY | -123.25% |
| 2013 FY | 2.59 Billion JPY | 131.11% |
| 2013 Q2 | 622.11 Million JPY | 458.95% |
| 2013 Q4 | 1.17 Billion JPY | 44.26% |
| 2013 Q3 | 817.55 Million JPY | 31.42% |
| 2012 Q4 | 745.55 Million JPY | 147.55% |
| 2012 Q2 | 247.58 Million JPY | 178.04% |
| 2012 FY | 1.12 Billion JPY | 117.67% |
| 2012 Q1 | -317.25 Million JPY | -211.48% |
| 2012 Q3 | 301.17 Million JPY | 21.64% |
| 2011 Q3 | 299.15 Million JPY | 20.38% |
| 2011 Q2 | 248.51 Million JPY | 134.39% |
| 2011 FY | 515 Million JPY | 141.45% |
| 2011 Q1 | -722.74 Million JPY | -309.81% |
| 2011 Q4 | 284.58 Million JPY | -4.87% |
| 2010 Q3 | -117.13 Million JPY | 48.24% |
| 2010 Q1 | -520.96 Million JPY | -143.35% |
| 2010 Q4 | -176.36 Million JPY | -50.56% |
| 2010 FY | -1.24 Billion JPY | -149.92% |
| 2010 Q2 | -226.32 Million JPY | 56.56% |
| 2009 Q4 | 1.2 Billion JPY | 9.99% |
| 2009 Q3 | 1.09 Billion JPY | 52.66% |
| 2009 Q2 | 715.75 Million JPY | 814.24% |
| 2009 Q1 | 78.28 Million JPY | -84.92% |
| 2009 FY | 2.48 Billion JPY | 178.32% |
| 2008 FY | 894.37 Million JPY | 33.06% |
| 2008 Q4 | 519.22 Million JPY | 0.0% |
| 2007 FY | 672.14 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 160.219% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 101.438% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 99.131% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 101.796% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | -1474.847% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 109.81% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 132.366% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 105.765% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | 530.028% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 123.384% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 153.059% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | 256.772% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | -523.279% |
| Tsumura & Co. | 20.01 Billion JPY | 115.381% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 176.649% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 161.14% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 117.447% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | 179.808% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 131.688% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 151.206% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 179.07% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | -279.342% |
| MedRx Co., Ltd | -933 Million JPY | -230.011% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 159.763% |
| Solasia Pharma K.K. | -1.13 Billion JPY | -170.325% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | -29.916% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 147.369% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 116.303% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | -341.474% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 115.928% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 170.26% |